Trial Profile
A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Atenolol (Primary) ; Fimasartan (Primary)
- Indications Essential hypertension
- Focus Biomarker; Therapeutic Use
- Sponsors Boryung Pharmaceutical
- 21 Sep 2016 Status changed from recruiting to completed.
- 31 Aug 2015 Planned primary completion date changed from 1 Nov 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 07 Jan 2013 New trial record